The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Comprehensive molecular portraits of human breast tumours
Open accessAbstract
We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype. We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signalling pathways dominant in each molecular subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype. Comparison of basal-like breast tumours with high-grade serous ovarian tumours showed many molecular commonalities, indicating a related aetiology and similar therapeutic opportunities. The biological finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biological subtypes of breast cancer. The Cancer Genome Atlas Network describe their multifaceted analyses of primary breast cancers, shedding light on breast cancer heterogeneity; although only three genes (TP53, PIK3CA and GATA3) are mutated at a frequency greater than 10% across all breast cancers, numerous subtype-associated and novel mutations were identified. This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary breast cancers in 825 people. Exome sequencing, copy number variation, DNA methylation, messenger RNA arrays, microRNA sequencing and proteomic analyses were performed and integrated to shed light on breast-cancer heterogeneity. Just three genes — TP53, PIK3CA and GATA3 — are mutated at greater than 10% frequency across all breast cancers. Many subtype-associated and novel mutations were identified, as well as two breast-cancer subgroups with specific signalling-pathway signatures. The analyses also suggest that much of the clinically observable plasticity and heterogeneity occurs within, and not across, the major subtypes of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In breast cancer, hypoxia is more evident in TNBC than in other breast cancer subtypes11,12.”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia-inducible factor 1α (HIF-1α) is a master transcription factor that is highly expressed in cancer tissues, including breast cancer, and is particularly enriched in triple-negative breast cancer (TNBC)2.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“A recent analysis, combining mutation, mRNA expression and protein levels, determined that the PI3K/Akt pathway was elevated in basal-like cancers as compared with luminal or HER2+ (47).”
From Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer (2014) · cites this paper as [47]
In the citing paper
“data analysis of The Cancer Genome Atlas (TCGA) dataset11 identified that hypoxic gene signature, which includes commonly documented hypoxia-responsive genes26, was inversely correlated with immune effector genes (IFNG, TNF, GZMB, PRF1), IFNγ-responsive genes, as well as genes associated with tumor-infiltrating lymphocytes (TILs) in TNBC (n = 99) (also referred as a basal subtype of breast cancer)”
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
In the citing paper
“Analysis of hundreds of triple-negative breast cancers revealed a wide diversity of somatic mutations none of which were found at high frequency [4].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
In the citing paper
“Given the remarkable overexpression of HIF target genes in triple-negative breast cancer [4, 21], the master regulatory role of HIFs in metastasis (Fig. 5), and their involvement in chemotherapy resistance, HIF inhibitors may represent a targeted therapy for these breast cancers.”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J. B., Cronin, M. T., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,321
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Cited by
Sorted by citations
Items 901–1,000 of 1,085
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Lev, S. (2020) · Biochemical Society Transactions · doi:10.1042/bst20191055 · Cited by 172
Martins-Cardoso, K., de Almeida, V. H., Bagri, K. M., Rossi, M. I. D., Mermelstein, C., König, S., & Monteiro, R. Q. (2020) · Cancers · doi:10.3390/cancers12061542 · Cited by 172
Age-specific changes in intrinsic breast cancer subtypes: a focus on older women
Jenkins, E. O., Deal, A. M., Anders, C. K., Prat, A., Perou, C. M., Carey, L. A., & Muss, H. B. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0184 · Cited by 165
Zhu, Y., Li, H., Guo, W., Drukker, K., Lan, L., Giger, M. L., & Ji, Y. (2015) · Scientific Reports · doi:10.1038/srep17787 · Cited by 165
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Tien, J. F., Mazloomian, A., Cheng, S., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo‐Gonzalez, G., Bashashati, A., Xu, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx187 · Cited by 169
Gene set enrichment analysis for genome-wide DNA methylation data
Maksimovic, J., Oshlack, A., & Phipson, B. (2021) · Genome biology · doi:10.1186/s13059-021-02388-x · Cited by 182
Liu, W., Xie, L., He, Y.-H., Wu, Z.-Y., Liu, L.-X., Bai, X., Deng, D.-X., Xu, X., Liao, L.-D., Lin, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25202-5 · Cited by 178
The origin of breast tumor heterogeneity
Skibinski, A., & Kuperwasser, C. (2015) · Oncogene · doi:10.1038/onc.2014.475 · Cited by 179
APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma
Leonard, B. C., Hart, S. N., Burns, M. B., Carpenter, M. A., Temiz, N. A., Rathore, A. S., Vogel, R. I., Nikas, J. B., Law, E. K., Brown, W. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1753 · Cited by 164
Lobular breast cancer: Clinical, molecular and morphological characteristics
Christgen, M., Steinemann, D., Kühnle, E., Länger, F. P., Gluz, O., Harbeck, N., & Kreipe, H. H. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.05.002 · Cited by 164
Comparison of somatic mutation calling methods in amplicon and whole exome sequence data
Xu, H., DiCarlo, J., Satya, R. V., Peng, Q., & Wang, Y. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-244 · Cited by 163
Harnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 165
Jadaliha, M., Zong, X., Malakar, P., Ray, T., Singh, D. K., Freier, S. M., Jensen, T., Prasanth, S. G., Karni, R., Ray, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9622 · Cited by 163
Fu, X., Pereira, R., Angelis, C. D., Veeraraghavan, J., Nanda, S., Qin, L., Cataldo, M. L., Sethunath, V., Mehravaran, S., Gutiérrez, C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911584116 · Cited by 167
Craven, K. E., Gökmen‐Polar, Y., & Badve, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83913-7 · Cited by 163
A benchmark study of deep learning-based multi-omics data fusion methods for cancer
Leng, D., Zheng, L., Wen, Y., Zhang, Y., Wu, L., Wang, J., Wang, M., Zhang, Z., He, S., & Bo, X. (2022) · Genome biology · doi:10.1186/s13059-022-02739-2 · Cited by 163
Fassbender, A., Rahmioglu, N., Vitonis, A. F., Viganò, P., Giudice, L. C., D’Hooghe, T. M., Hummelshoj, L., Adamson, G. D., Becker, C. M., Missmer, S. A., et al. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.07.1209 · Cited by 162
Tang, W., Zhou, M., Dorsey, T. H., Prieto, D. A., Wang, X. W., Ruppin, E., Veenstra, T. D., & Ambs, S. (2018) · Genome Medicine · doi:10.1186/s13073-018-0602-x · Cited by 162
“These findings were corroborated using proteome and transcriptome data for 404 breast tumors from “ The Cancer Genome Atlas ” (TCGA) and 77 breast tumors from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) [13, 17].”
Naipal, K. A. T., Verkaik, N. S., Ameziane, N., van Deurzen, C. H. M., ter Brugge, P., Meijers, M., Sieuwerts, A. M., Martens, J. W. M., O’Connor, M. J., Vrieling, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0571 · Cited by 168
Lee, H. J., Park, I. A., Song, I. H., Shin, S., Kim, J. Y., Yu, J. H., & Gong, G. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203089 · Cited by 162
Danilova, L., Wang, H., Sunshine, J. C., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 164
Network-based integration of multi-omics data for prioritizing cancer genes
Dimitrakopoulos, C. M., Hindupur, S. K., Häfliger, L., Behr, J., Montazeri, H., Hall, M. N., & Beerenwinkel, N. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty148 · Cited by 166
Vijay, G. V., Zhao, N., den Hollander, P., Toneff, M. J., Joseph, R., Pietilä, M., Taube, J. H., Sarkar, T. R., Ramirez‐Peña, E., Werden, S. J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1125-0 · Cited by 162
Molecular and cellular mechanisms underlying brain metastasis of breast cancer
Hosonaga, M., Saya, H., & Arima, Y. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09881-y · Cited by 163
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer
Arend, R. C., Londoño-Joshi, A. I., Samant, R. S., Li, Y., Conner, M., Hidalgo, B., Alvarez, R. D., Landen, C. N., Straughn, J. M., & Buchsbaum, D. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.005 · Cited by 161
Si, W., Huang, W., Zheng, Y., Yang, Y., Liu, X., Shan, L., Zhou, X., Wang, Y., Su, D., Gao, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.011 · Cited by 161
The complex genetic landscape of familial breast cancer
Melchor, L., & Benitez, J. J. (2013) · Human Genetics · doi:10.1007/s00439-013-1299-y · Cited by 174
The cancer COMPASS: navigating the functions of MLL complexes in cancer
Ford, D. J., & Dingwall, A. K. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.01.005 · Cited by 169
Babur, Ö., Gönen, M., Aksoy, B. A., Schultz, N. D., Ciriello, G., Sander, C., & Demir, E. (2015) · Genome biology · doi:10.1186/s13059-015-0612-6 · Cited by 163
Epithelial ovarian cancer: An overview
Desai, A. (2014) · World Journal of Translational Medicine · doi:10.5528/wjtm.v3.i1.1 · Cited by 161
Janiszewska, M., Liu, L., Almendro, V., Kuang, Y., Paweletz, C. P., Sakr, R. A., Weigelt, B., Hanker, A. B., Chandarlapaty, S., King, T. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3391 · Cited by 163
Malorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 163
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Ng, C. K. Y., Piscuoglio, S., Geyer, F. C., Burke, K. A., Pareja, F. G., Eberle, C. A., Lim, R. S., Natrajan, R., Riaz, N., Mariani, O., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2857 · Cited by 164
Combating subclonal evolution of resistant cancer phenotypes
Brady, S. W., McQuerry, J. A., Qiao, Y., Piccolo, S., Shrestha, G., Jenkins, D. F., Layer, R. M., Pedersen, B. S., Miller, R. H., Esch, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01174-3 · Cited by 163
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
Corona, S. P., & Generali, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s137783 · Cited by 162
Johnson, D. B., Nixon, M. J., Wang, Y., Wang, D. Y., Castellanos, E. H., Estrada, M. V., Ericsson, P. I. G., Cote, C. H., Salgado, R., Sanchez, V. M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120360 · Cited by 161
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers
Kong, T., Ahn, R., Yang, K., Zhu, X., Fu, Z., Morin, G., Bramley, R., Cliffe, N. C., Xue, Y., Kuasne, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1108 · Cited by 162
Exploring the multiple roles of guardian of the genome: P53
Feroz, W., & Sheikh, A. M. A. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00089-x · Cited by 172
Li, X., Ma, J., Leng, L., Han, M., Li, M., He, F., & Zhu, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.806842 · Cited by 161
Migliorini, G., Fiege, B., Hosking, F. J., Ma, Y. P., Kumar, R., Sherborne, A. L., Filho, M. I. D. S., Vijayakrishnan, J., Koehler, R., Thomsen, H., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491316 · Cited by 164
Ong, P. S., Wang, L. Z., Dai, X., Tseng, S. H., Loo, S. J., & Sethi, G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00395 · Cited by 162
RNA Biomarkers: Frontier of Precision Medicine for Cancer
Xi, X., Li, T., Huang, Y., Sun, J., Zhu, Y., Yang, Y., & Lu, Z. J. (2017) · Non-Coding RNA · doi:10.3390/ncrna3010009 · Cited by 163
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J., White, H. S., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 165
Detecting repeated cancer evolution from multi-region tumor sequencing data
Caravagna, G., Giarratano, Y., Ramazzotti, D., Tomlinson, I. P. M., Graham, T. A., Sanguinetti, G., & Sottoriva, A. (2018) · Nature Methods · doi:10.1038/s41592-018-0108-x · Cited by 162
An Update on Breast Cancer Multigene Prognostic Tests—Emergent Clinical Biomarkers
Vieira, A. F., & Schmitt, F. C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00248 · Cited by 166
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Razavi, P., Dickler, M. N., Shah, P. D., Toy, W., Brown, D. N., Won, H. H., Li, B. T., Shen, R., Vasan, N., Modi, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0047-1 · Cited by 163
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics
Anders, C. K., Abramson, V. G., Tan, T. J., & Dent, R. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159135 · Cited by 170
Dysregulation and therapeutic targeting of RNA splicing in cancer
Stanley, R. F., & Abdel-Wahab, O. I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00384-z · Cited by 172
Looking beyond the hype: applied AI and machine learning in translational medicine
Toh, T. S., Dondelinger, F., & Wang, D. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.027 · Cited by 159
Lin, C., Pelissier, F. A., Zhang, H., Lakins, J. N., Weaver, V. M., Park, C., & LaBarge, M. A. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-07-0456 · Cited by 167
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
Wagner, A. H., Devarakonda, S. H. K., Skidmore, Z. L., Krysiak, K., Ramu, A., Trani, L., Kunisaki, J., Masood, A., Waqar, S. N., Spies, N. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06162-9 · Cited by 160
Yu, K., Chen, B., Aran, D., Charalel, J. K., Yau, C. S. F., Wolf, D. M., Veer, L. V. ‘., Butte, A. J., Goldstein, T. C., & Sirota, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11415-2 · Cited by 165
Recent treatment progress of triple negative breast cancer
Yang, C., Liu, J., Zhao, S., Kun, Z., Zi-Qian, G., Xu, R., Lu, H., Zhou, R., Zhao, G., Yin, D., et al. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.11.007 · Cited by 159
The mutational landscape of phosphorylation signaling in cancer
Reimand, J., Wagih, O., & Bader, G. D. (2013) · Scientific Reports · doi:10.1038/srep02651 · Cited by 163
Kurozumi, S., Yamaguchi, Y., Kurosumi, M., Ohira, M., Matsumoto, H., & Horiguchi, J. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2016.89 · Cited by 159
Goh, J. Y., Feng, M., Wang, W., Oguz, G., Yatim, S. M. J. M., Lee, P. L., Bao, Y., Lim, T. H., Wang, P., Tam, W. L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4405 · Cited by 158
Giraddi, R. R., Chung, C., Heinz, R. E., Balcioglu, O., Novotny, M. A., Trejo, C. L., Dravis, C., Hagos, B. M., Mehrabad, E. M., Rodewald, L. W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.025 · Cited by 163
Veeraraghavan, J., Tan, Y., Cao, X.-X., Kim, J. A., Wang, X., Chamness, G. C., Maiti, S. N., Cooper, L. J. N., Edwards, D. P., Contreras, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5577 · Cited by 161
Skibinski, A., Breindel, J. L., Prat, A., Galván, P., Smith, E., Rolfs, A., Gupta, P. B., LaBaer, J., & Kuperwasser, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.038 · Cited by 160
Intratumor Heterogeneity in Breast Cancer
de Beça, F. F., & Polyák, K. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22909-6_7 · Cited by 160
Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update
Tang, P. T. P., & Tse, G. M.-K. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0133-ra · Cited by 157
Highly specific imaging of mRNA in single cells by target RNA-initiated rolling circle amplification
Deng, R., Zhang, K., Sun, Y., Ren, X., & Li, J. (2017) · Chemical Science · doi:10.1039/c7sc00292k · Cited by 157
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Felsenstein, K. M., & Theodorescu, D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.179 · Cited by 159
TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer
Good, C. R., Panjarian, S. B., Kelly, A. D., Madžo, J., Patel, B. G., Jelı́nek, J., & Issa, J. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2082 · Cited by 157
Prat, A., Guarneri, V., Pascual, T., Brasó‐Maristany, F., Sanfeliu, E., Paré, L., Schettini, F., Martínez, D., Jares, P., Griguolo, G., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103801 · Cited by 157
Morphological and molecular breast cancer profiling through explainable machine learning
Binder, A., Bockmayr, M., Hägele, M., Wienert, S., Heim, D., Hellweg, K., Ishii, M., Stenzinger, A., Hocke, A., Denkert, C., et al. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00303-4 · Cited by 156
Wang, J., Ma, Z., Carr, S. A., Mertins, P., Zhang, H., Zhang, Z., Chan, D. W., Ellis, M. J., Townsend, R. R., Smith, R. D., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.060301 · Cited by 160
TRIP13 regulates DNA repair pathway choice through REV7 conformational change
Clairmont, C. S., Sarangi, P., Ponnienselvan, K., Galli, L. D., Csete, I., Moreau, L. A., Adelmant, G., Chowdhury, D., Marto, J. A., & D’Andrea, A. D. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0442-y · Cited by 161
Ou, X., Tan, Y., Xie, J., Yuan, J., Deng, X., Shao, R., Song, C., Cao, X., Xie, X., He, R., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101063 · Cited by 156
Determining breast cancer biomarker status and associated morphological features using deep learning
Gamble, P., Jaroensri, R., Wang, H., Tan, F., Moran, M., Brown, T., Flament-Auvigne, I., Rakha, E. A., Toss, M., Dabbs, D. J., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00013-3 · Cited by 154
An integrative multi-scale analysis of the dynamic DNA methylation landscape in aging
Yuan, T., Jiao, Y., de Jong, S., Ophoff, R. A., Beck, S., & Teschendorff, A. E. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1004996 · Cited by 155
Genomic landscape of adenoid cystic carcinoma of the breast
Martelotto, L. G., Filippo, M. R. D., Ng, C. K. Y., Natrajan, R., Fuhrmann, L., Cyrta, J., Piscuoglio, S., Wen, H., Lim, R. S., Shen, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4573 · Cited by 157
Balko, J. M., Schwarz, L. J., Bhola, N. E., Kurupi, R., Owens, P., Miller, T. W., Gómez, H., Cook, R. S., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1385 · Cited by 158
Hefti, M. M., Hu, R., Knoblauch, N., Collins, L. C., Haibe‐Kains, B., Tamimi, R. M., & Beck, A. H. (2013) · Breast Cancer Research · doi:10.1186/bcr3462 · Cited by 155
Long non-coding RNAs as prognostic markers in human breast cancer
Liu, H., Li, J., Koirala, P., Ding, X., Chen, B., Wang, Y., Wang, Z., Wang, C., Zhang, X., & Mo, Y.-Y. (2016) · Oncotarget · doi:10.18632/oncotarget.7828 · Cited by 155
Molecular subtypes and imaging phenotypes of breast cancer
Cho, N. (2016) · ULTRASONOGRAPHY · doi:10.14366/usg.16030 · Cited by 155
Molecular profiling of driver events in metastatic uveal melanoma
Karlsson, J. W., Nilsson, L. M., Mitra, S., Alsén, S., Shelke, G. V., Sah, V. R., Forsberg, E. M. V., Stierner, U. K., All‐Eriksson, C., Einarsdottir, B. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15606-0 · Cited by 155
Zhao, Q., Shi, X., Xie, Y., Huang, J., Shia, B., & Ma, S. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbu003 · Cited by 154
Characterization of the Usage of the Serine Metabolic Network in Human Cancer
Mehrmohamadi, M., Liu, X., Shestov, A. A., & Locasale, J. W. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.026 · Cited by 158
Naeem, H., Wong, N. C., Chatterton, Z., Hong, M. K. H., Pedersen, J. S., Corcoran, N. M., Hovens, C. M., & Macintyre, G. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-51 · Cited by 157
BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells
Khaled, W. T., Lee, S. C., Stingl, J., Chen, X., Ali, H. R., Rueda, O. M., Hadi, F., Wang, J., Yu, Y., Chin, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms6987 · Cited by 158
Targeting Akt3 Signaling in Triple-Negative Breast Cancer
Chin, Y. R., Yoshida, T., Marusyk, A., Beck, A. H., Polyák, K., & Toker, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2175 · Cited by 157
DNA methylation–based immune response signature improves patient diagnosis in multiple cancers
Jeschke, J., Bizet, M., Desmedt, C., Calonne, E., Dedeurwaerder, S., Garaud, S., Koch, A., Larsimont, D., Salgado, R., den Eynden, G. V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91095 · Cited by 157
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Joshi, J. J., Coffey, H., Corcoran, E., Tsai, J. J.-Y., Huang, C. L., Ichikawa, K., Prajapati, S., Hao, M., Bailey, S., Wu, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1865 · Cited by 156
Patient Similarity Networks for Precision Medicine
Pai, S., & Bader, G. D. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.037 · Cited by 159
Going Digital: A Survey on Digitalization and Large-Scale Data Analytics in Healthcare
Volker Tresp, C., Overhage, J. M., Bundschus, M., Rabizadeh, S., Fasching, P. A., & Yu, S. (2016) · Proceedings of the IEEE · doi:10.1109/jproc.2016.2615052 · Cited by 162
M3C: Monte Carlo reference-based consensus clustering
John, C. R., Watson, D., Russ, D., Goldmann, K., Ehrenstein, M. R., Pitzalis, C., Lewis, M., & Barnes, M. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-58766-1 · Cited by 159
Khorsandi, K., Kianmehr, Z., hosseinmardi, Z., & Hosseinzadeh, R. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1100-y · Cited by 154
Artificial intelligence for breast cancer analysis: Trends & directions
Shah, S. M., Khan, R. A., Arif, S., & Sajid, U. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105221 · Cited by 160
Wang, K., Zhang, Q., Li, D., Ching, K. A., Zhang, C., Zheng, X., Ozeck, M., Shi, S. T., Li, X., Wang, H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1348 · Cited by 155
Gallo, L. H., Nelson, K. N., Meyer, A. N., & Donoghue, D. J. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.03.003 · Cited by 155
Nasser, M. W., Wani, N. A., Ahirwar, D. K., Powell, C. A., Ravi, J., Elbaz, M., Zhao, H., Padilla, L., Zhang, X., Shilo, K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2161 · Cited by 156
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
Zardavas, D., Phillips, W. A., & Loi, S. (2014) · Breast Cancer Research · doi:10.1186/bcr3605 · Cited by 161
PGC-1α supports glutamine metabolism in breast cancer
McGuirk, S., Gravel, S., Deblois, G., Papadopoli, D. J., Faubert, B., Wegner, A., Hiller, K., Avizonis, D. Z., Akavia, U. D., Jones, R. G., et al. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-22 · Cited by 160
Breakable Hybrid Organosilica Nanocapsules for Protein Delivery
Prasetyanto, E. A., Bertucci, A., Septiadi, D., Corradini, R., Castro‐Hartmann, P., & Cola, L. D. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201508288 · Cited by 157
Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)
Wein, L., & Loi, S. (2017) · The Breast · doi:10.1016/j.breast.2017.06.023 · Cited by 153
Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies
He, M. Y., Rancoule, C., Rehailia-Blanchard, A., Espenel, S., Trone, J., Bernichon, E., Guillaume, E., Vallard, A., & Magné, N. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.004 · Cited by 153
Metabolic Adaptations in Cancer Stem Cells
Yadav, U. P., Singh, T., Kumar, P., Sharma, P., Kaur, H., Sharma, S., Singh, S., Kumar, S., & Mehta, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01010 · Cited by 158
A survey on graph-based deep learning for computational histopathology
Ahmedt‐Aristizabal, D., Armin, M. A., Denman, S., Fookes, C., & Petersson, L. (2021) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2021.102027 · Cited by 165
Zimmerli, D., Brambillasca, C. S., Talens, F., Bhin, J., Linstra, R., Romanens, L., Bhattacharya, A., Joosten, S. E. P., Silva, A. M. D., Padrão, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34000-6 · Cited by 163
Metadata
- Authors
- The Cancer Genome Atlas Network
- Corresponding author
- The Cancer Genome Atlas Network
- Venue
- Nature
- Published
- 2012-09-23
- Volume
- 490
- Issue
- 7418
- Pages
- 61-70
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3465532
- OpenAlex
- W4301159569
- Cited by
- 12,129
- References
- 56
- Citations by year
- 2026: 552 · 2025: 690 · 2024: 761 · 2023: 781 · 2022: 918 · 2021: 1164 · 2020: 1005 · 2019: 961 · 2018: 942 · 2017: 949 · 2016: 979 · 2015: 909 · 2014: 879 · 2013: 590 · 2012: 40
- FWCI
- 256.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense
- Breast Cancer Research Foundation (P50CA116201)
- Henry M. Jackson Foundation
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG004028)
- National Cancer Institute (R01CA094143, U24CA143882, U01CA084955, U24CA143840, U24CA143858, U24CA144025, K08CA148912, U24CA143866, U24CA143883, U24CA143845, U24CA143867, U24CA143848, U24CA143799, U24CA143835, P50 CA 58223, P30CA016672, P30CA016058, P50CA058223, P50CA116201, P30CA016086)
- U.S. National Library of Medicine (R01LM009722)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast cancer, molecular subtypes, tumor heterogeneity, somatic mutations, TP53, PIK3CA, GATA3, MAP3K1, luminal A, HER2-enriched breast cancer, basal-like breast cancer, high-grade serous ovarian cancer, DNA methylation, copy number variation, gene expression signatures, signaling pathways, tumor microenvironment, multi-omics integration
- MeSH terms
- Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Mutation, Ovarian Neoplasms, Receptors, Estrogen, RNA, Messenger, RNA, Neoplasm, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Retinoblastoma Protein, Genes, erbB-2, Genetic Heterogeneity, DNA Methylation, Genes, BRCA1, Phosphatidylinositol 3-Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, MicroRNAs, Protein Array Analysis, Proteomics, MAP Kinase Kinase Kinase 1, GATA3 Transcription Factor, Genes, Neoplasm, DNA Copy Number Variations, Class I Phosphatidylinositol 3-Kinases, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
